Optimized immunohistochemical panel to differentiate myeloid sarcoma from blastic plasmacytoid dendritic cell neoplasm

Nikhil Sangle(Western University), Mohamed E. Salama(The University of Texas at San Antonio Health Science Center), L. Jeffrey Medeiros(Delaware Division of Libraries), Robert L. Schmidt, Sherrie L. Perkins(University of Utah), Archana M. Agarwal(University of Utah), Jay Patel(University of Utah)

Modern Pathology

January 3, 2014

10.1038/modpathol.2013.238

Cited by 54

Related Papers

Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation

|Cancer Cell|2010|2.7k

Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies

|Blood|2009|718

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program

|Blood|2013|683

MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition

|Cancer Cell|2017|619

Spectrum of Epithelial Neoplasms in End-Stage Renal Disease

|The American Journal of Surgical Pathology|2006|484